Gapping up
In reaction to earnings/guidance:
- MRVL +21.3%, SMAR +16.5%, TLYS +9.8%, ZG +9.4%, HIBB +6.9%, GCO +5.9%, ULTA +5.6%, SYNA +4.9%, ZUMZ +4%, JOAN +2.3%, BMO +1.9%, YEXT +1.1%, DOLE +0.7%
Other news:
- ENFA +8.1% (received shareholder approval for BuzzFeed combination)
- SYNA +4.9% (completes acquisition of DSP Group; updates Q2 guidance to include DSPs expected contribution)
- SBGI +4.2% (subsidiary Diamond Sports Group announced multi-year renewal of digital rights agreement with the NHL)
- KZIA +2.9% (final data from phase II clinical study of paxalisib in newly diagnosed glioblastoma)
- FOLD +2.9% (European Medicines Agency validates amicus therapeutics marketing authorization applications for AT-GAA for the treatment of pompe disease)
- NUE +2.5% (raises quarterly dividend by 23%to $0.50 per share; authorizes new $4 bln share repurchase program)
- RIOT +2.2% (provided November production and operations update)
- XENE +1.7% (provides updates on proprietary neurology pipeline programs at the Annual Meeting of the American Epilepsy Society; Presents Additional Positive Data from Phase 2b ‘X-TOLE' Clinical Trial at the Annual Meeting of the American Epilepsy Society)
- FIZZ +1.5% (announced special cash dividend)
- HCM +1.5% (HUTCHMED announces agreement with NHSA for continued inclusion of ELUNATE and addition of SULANDA in the National Reimbursement Drug List in China)
- ENBL +1.4% (closed combination with Energy Transfer [ET])
- VERI +1.1% (announces contract for aiWARE with the Environmental Protection Agency)
- NDAQ +1% (reports November 2021 metrics)
- BGNE +0.9% (announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications BRUKINSA (Zanubrutinib) in one new indication and the first listing for Pamiparib; also receives approval of SYLVANT from China's NMPA)
Analyst comments:
- CDTX +6.2% (assumed with a Buy at H.C. Wainwright; tgt $6)
- APPN +3% (upgraded to Equal-Weight from Underweight at Morgan Stanley)